- Home
- ESPR vs XNCR Comparison
ESPR vs XNCR Comparison
Compare ESPR & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESPR
- XNCR
- Stock Information
- Founded
- ESPR 2008
- XNCR 1997
- Country
- ESPR United States
- XNCR United States
- Employees
- ESPR N/A
- XNCR N/A
- Industry
- ESPR Biotechnology: Pharmaceutical Preparations
- XNCR Biotechnology: Pharmaceutical Preparations
- Sector
- ESPR Health Care
- XNCR Health Care
- Exchange
- ESPR Nasdaq
- XNCR Nasdaq
- Market Cap
- ESPR 534.3M
- XNCR 547.8M
- IPO Year
- ESPR 2013
- XNCR 2013
- Fundamental
- Price
- ESPR $2.55
- XNCR $12.35
- Analyst Decision
- ESPR Buy
- XNCR Buy
- Analyst Count
- ESPR 6
- XNCR 11
- Target Price
- ESPR $6.50
- XNCR $22.20
- AVG Volume (30 Days)
- ESPR 7.0M
- XNCR 1.2M
- Earning Date
- ESPR 11-06-2025
- XNCR 11-05-2025
- Dividend Yield
- ESPR N/A
- XNCR N/A
- EPS Growth
- ESPR N/A
- XNCR N/A
- EPS
- ESPR N/A
- XNCR N/A
- Revenue
- ESPR $268,125,000.00
- XNCR $146,929,000.00
- Revenue This Year
- ESPR $13.05
- XNCR $23.31
- Revenue Next Year
- ESPR N/A
- XNCR N/A
- P/E Ratio
- ESPR N/A
- XNCR N/A
- Revenue Growth
- ESPR N/A
- XNCR N/A
- 52 Week Low
- ESPR $0.69
- XNCR $6.92
- 52 Week High
- ESPR $3.94
- XNCR $27.24
- Technical
- Relative Strength Index (RSI)
- ESPR 47.71
- XNCR 81.61
- Support Level
- ESPR $2.35
- XNCR $11.36
- Resistance Level
- ESPR $3.41
- XNCR $12.63
- Average True Range (ATR)
- ESPR 0.18
- XNCR 0.54
- MACD
- ESPR -0.03
- XNCR 0.10
- Stochastic Oscillator
- ESPR 9.79
- XNCR 79.86
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.